CA2946593A1 - Aav vectors for retinal and cns gene therapy - Google Patents
Aav vectors for retinal and cns gene therapy Download PDFInfo
- Publication number
- CA2946593A1 CA2946593A1 CA2946593A CA2946593A CA2946593A1 CA 2946593 A1 CA2946593 A1 CA 2946593A1 CA 2946593 A CA2946593 A CA 2946593A CA 2946593 A CA2946593 A CA 2946593A CA 2946593 A1 CA2946593 A1 CA 2946593A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- numbering
- raav
- nucleic acid
- acid substitutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 19
- 239000013598 vector Substances 0.000 title claims description 27
- 238000001415 gene therapy Methods 0.000 title abstract description 9
- 238000006467 substitution reaction Methods 0.000 claims abstract description 712
- 239000002245 particle Substances 0.000 claims abstract description 409
- 238000000034 method Methods 0.000 claims abstract description 288
- 108091016585 CD44 antigen Proteins 0.000 claims abstract description 116
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims abstract description 116
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 116
- 108090000054 Syndecan-2 Proteins 0.000 claims abstract description 116
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 103
- 150000001413 amino acids Chemical class 0.000 claims abstract description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 53
- 238000010361 transduction Methods 0.000 claims abstract description 41
- 230000026683 transduction Effects 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 208000022873 Ocular disease Diseases 0.000 claims abstract description 30
- 208000035475 disorder Diseases 0.000 claims abstract description 18
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 8
- 235000001014 amino acid Nutrition 0.000 claims description 528
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 519
- 150000007523 nucleic acids Chemical class 0.000 claims description 368
- 102000039446 nucleic acids Human genes 0.000 claims description 302
- 108020004707 nucleic acids Proteins 0.000 claims description 302
- 210000000234 capsid Anatomy 0.000 claims description 236
- 210000004027 cell Anatomy 0.000 claims description 193
- 108090000565 Capsid Proteins Proteins 0.000 claims description 122
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 122
- 230000001225 therapeutic effect Effects 0.000 claims description 122
- 210000003169 central nervous system Anatomy 0.000 claims description 114
- 125000000539 amino acid group Chemical group 0.000 claims description 112
- 229920001184 polypeptide Polymers 0.000 claims description 91
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 239000013608 rAAV vector Substances 0.000 claims description 81
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 66
- 239000004475 Arginine Substances 0.000 claims description 50
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 50
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 50
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 50
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 47
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 47
- 210000001525 retina Anatomy 0.000 claims description 47
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 46
- 241000649044 Adeno-associated virus 9 Species 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 40
- 210000002569 neuron Anatomy 0.000 claims description 36
- 241000701022 Cytomegalovirus Species 0.000 claims description 35
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 33
- 208000002780 macular degeneration Diseases 0.000 claims description 33
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 31
- 210000004556 brain Anatomy 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 29
- 230000002209 hydrophobic effect Effects 0.000 claims description 28
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 20
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 claims description 20
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 claims description 20
- 108091030071 RNAI Proteins 0.000 claims description 20
- 108090000799 Rhodopsin kinases Proteins 0.000 claims description 20
- 230000009368 gene silencing by RNA Effects 0.000 claims description 20
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 20
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 18
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 16
- 210000001130 astrocyte Anatomy 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 108091070501 miRNA Proteins 0.000 claims description 16
- 239000002679 microRNA Substances 0.000 claims description 16
- 230000002025 microglial effect Effects 0.000 claims description 16
- 210000004248 oligodendroglia Anatomy 0.000 claims description 16
- 210000000449 purkinje cell Anatomy 0.000 claims description 16
- 241000287828 Gallus gallus Species 0.000 claims description 15
- -1 NF.kappa.B Proteins 0.000 claims description 15
- 241000714474 Rous sarcoma virus Species 0.000 claims description 15
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 14
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 14
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 210000001127 pigmented epithelial cell Anatomy 0.000 claims description 14
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 12
- 108020005544 Antisense RNA Proteins 0.000 claims description 12
- 108090000994 Catalytic RNA Proteins 0.000 claims description 12
- 102000053642 Catalytic RNA Human genes 0.000 claims description 12
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 12
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 12
- 208000023105 Huntington disease Diseases 0.000 claims description 12
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 12
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 201000007737 Retinal degeneration Diseases 0.000 claims description 12
- 208000027073 Stargardt disease Diseases 0.000 claims description 12
- 208000005400 Synovial Cyst Diseases 0.000 claims description 12
- 208000014769 Usher Syndromes Diseases 0.000 claims description 12
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 12
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 12
- 239000003184 complementary RNA Substances 0.000 claims description 12
- 239000003900 neurotrophic factor Substances 0.000 claims description 12
- 230000004258 retinal degeneration Effects 0.000 claims description 12
- 108091092562 ribozyme Proteins 0.000 claims description 12
- 230000004382 visual function Effects 0.000 claims description 12
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims description 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 11
- 102400000068 Angiostatin Human genes 0.000 claims description 10
- 108010079709 Angiostatins Proteins 0.000 claims description 10
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 10
- 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 claims description 10
- 108091012583 BCL2 Proteins 0.000 claims description 10
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 10
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 claims description 10
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 claims description 10
- 208000033379 Chorioretinopathy Diseases 0.000 claims description 10
- 208000002691 Choroiditis Diseases 0.000 claims description 10
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims description 10
- 208000006992 Color Vision Defects Diseases 0.000 claims description 10
- 102100029362 Cone-rod homeobox protein Human genes 0.000 claims description 10
- 206010010356 Congenital anomaly Diseases 0.000 claims description 10
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 claims description 10
- 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 claims description 10
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 10
- 108010079505 Endostatins Proteins 0.000 claims description 10
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 10
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 10
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 claims description 10
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 claims description 10
- 101000594506 Homo sapiens Acyl-coenzyme A diphosphatase NUDT19 Proteins 0.000 claims description 10
- 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 claims description 10
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 claims description 10
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 claims description 10
- 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 claims description 10
- 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 claims description 10
- 101001008411 Homo sapiens Lebercilin Proteins 0.000 claims description 10
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 claims description 10
- 101000781361 Homo sapiens Protein XRP2 Proteins 0.000 claims description 10
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 claims description 10
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 claims description 10
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims description 10
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 10
- 101000742938 Homo sapiens Retinol dehydrogenase 12 Proteins 0.000 claims description 10
- 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 claims description 10
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 claims description 10
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 102100027443 Lebercilin Human genes 0.000 claims description 10
- 102100033356 Lecithin retinol acyltransferase Human genes 0.000 claims description 10
- 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 10
- 208000035719 Maculopathy Diseases 0.000 claims description 10
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 claims description 10
- 102000010175 Opsin Human genes 0.000 claims description 10
- 108050001704 Opsin Proteins 0.000 claims description 10
- 101150046816 PRPH2 gene Proteins 0.000 claims description 10
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 10
- 208000003971 Posterior uveitis Diseases 0.000 claims description 10
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 10
- 102100033154 Protein XRP2 Human genes 0.000 claims description 10
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 claims description 10
- 206010038848 Retinal detachment Diseases 0.000 claims description 10
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 claims description 10
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims description 10
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 10
- 102100038054 Retinol dehydrogenase 12 Human genes 0.000 claims description 10
- 101000733871 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-A Proteins 0.000 claims description 10
- 101000733875 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-B Proteins 0.000 claims description 10
- 102100029293 Tubby-related protein 1 Human genes 0.000 claims description 10
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 claims description 10
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 claims description 10
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 claims description 10
- 208000017441 X-linked retinoschisis Diseases 0.000 claims description 10
- 201000000761 achromatopsia Diseases 0.000 claims description 10
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 10
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 10
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 claims description 10
- 201000007254 color blindness Diseases 0.000 claims description 10
- 201000008615 cone dystrophy Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 108010084957 lecithin-retinol acyltransferase Proteins 0.000 claims description 10
- 210000001577 neostriatum Anatomy 0.000 claims description 10
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims description 10
- 230000004264 retinal detachment Effects 0.000 claims description 10
- 201000007714 retinoschisis Diseases 0.000 claims description 10
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 10
- 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 claims description 9
- 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 claims description 9
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 9
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims description 9
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 claims description 9
- 210000000411 amacrine cell Anatomy 0.000 claims description 9
- 210000002287 horizontal cell Anatomy 0.000 claims description 9
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 8
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 7
- 230000003959 neuroinflammation Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 6
- 208000015872 Gaucher disease Diseases 0.000 claims description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 6
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 6
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims description 5
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims description 5
- 108010071690 Prealbumin Proteins 0.000 claims description 5
- 108010017842 Telomerase Proteins 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 108010022394 Threonine synthase Proteins 0.000 claims description 5
- 102000009190 Transthyretin Human genes 0.000 claims description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 claims description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 4
- 102100032948 Aspartoacylase Human genes 0.000 claims description 4
- 108700023155 Aspartoacylases Proteins 0.000 claims description 4
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 claims description 4
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 4
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 102000036509 GTP Cyclohydrolase Human genes 0.000 claims description 4
- 108010023555 GTP Cyclohydrolase Proteins 0.000 claims description 4
- 102100028496 Galactocerebrosidase Human genes 0.000 claims description 4
- 108010042681 Galactosylceramidase Proteins 0.000 claims description 4
- 108010000540 Hexosaminidases Proteins 0.000 claims description 4
- 102000002268 Hexosaminidases Human genes 0.000 claims description 4
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 4
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims description 4
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 claims description 4
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 claims description 4
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims description 4
- 210000001638 cerebellum Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000004720 cerebrum Anatomy 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 4
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 210000002330 subarachnoid space Anatomy 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 230000004304 visual acuity Effects 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 108020005296 Acid Ceramidase Proteins 0.000 claims description 2
- 102000006772 Acid Ceramidase Human genes 0.000 claims description 2
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 claims description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 claims description 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102100022146 Arylsulfatase A Human genes 0.000 claims description 2
- 102100031491 Arylsulfatase B Human genes 0.000 claims description 2
- 102000009133 Arylsulfatases Human genes 0.000 claims description 2
- 108010023546 Aspartylglucosylaminase Proteins 0.000 claims description 2
- 101710195294 Beta-galactosidase 1 Proteins 0.000 claims description 2
- 102100026031 Beta-glucuronidase Human genes 0.000 claims description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 101710117545 C protein Proteins 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 102000005572 Cathepsin A Human genes 0.000 claims description 2
- 108010059081 Cathepsin A Proteins 0.000 claims description 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims description 2
- 208000037326 Gaucher disease type 1 Diseases 0.000 claims description 2
- 208000037310 Gaucher disease type 2 Diseases 0.000 claims description 2
- 208000037311 Gaucher disease type 3 Diseases 0.000 claims description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 2
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 2
- 102000053187 Glucuronidase Human genes 0.000 claims description 2
- 108010060309 Glucuronidase Proteins 0.000 claims description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 claims description 2
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims description 2
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 claims description 2
- 101000979046 Homo sapiens Lysosomal alpha-mannosidase Proteins 0.000 claims description 2
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 claims description 2
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 claims description 2
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 claims description 2
- 102000004627 Iduronidase Human genes 0.000 claims description 2
- 108010003381 Iduronidase Proteins 0.000 claims description 2
- 208000028226 Krabbe disease Diseases 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 2
- 102100023231 Lysosomal alpha-mannosidase Human genes 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 2
- 108010054377 Mannosidases Proteins 0.000 claims description 2
- 102000001696 Mannosidases Human genes 0.000 claims description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 2
- 208000008955 Mucolipidoses Diseases 0.000 claims description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 claims description 2
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims description 2
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 claims description 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims description 2
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 claims description 2
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 claims description 2
- 101710202061 N-acetyltransferase Proteins 0.000 claims description 2
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 claims description 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims description 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims description 2
- 101100449397 Rattus norvegicus Gpr6 gene Proteins 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 claims description 2
- 208000025802 Sanfilippo syndrome type C Diseases 0.000 claims description 2
- 101100401683 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mis13 gene Proteins 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 108700001567 Type I Schindler Disease Proteins 0.000 claims description 2
- 208000026589 Wolman disease Diseases 0.000 claims description 2
- WJFVEEAIYIOATH-KEWYIRBNSA-N [(2r,3r,4r,5r)-5-acetamido-3,4,6-trihydroxyoxan-2-yl]methyl hydrogen sulfate Chemical compound CC(=O)N[C@H]1C(O)O[C@H](COS(O)(=O)=O)[C@H](O)[C@@H]1O WJFVEEAIYIOATH-KEWYIRBNSA-N 0.000 claims description 2
- 108010070626 acid beta-galactosidase Proteins 0.000 claims description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 2
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 2
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 2
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 210000000576 arachnoid Anatomy 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 108010055059 beta-Mannosidase Proteins 0.000 claims description 2
- 108010046910 brain-derived growth factor Proteins 0.000 claims description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 210000004289 cerebral ventricle Anatomy 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 229940045896 cnl8 Drugs 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 210000001951 dura mater Anatomy 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000008049 fucosidosis Diseases 0.000 claims description 2
- 230000000574 ganglionic effect Effects 0.000 claims description 2
- 230000002518 glial effect Effects 0.000 claims description 2
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 2
- 201000008977 glycoproteinosis Diseases 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 210000003016 hypothalamus Anatomy 0.000 claims description 2
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 210000003140 lateral ventricle Anatomy 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 210000004705 lumbosacral region Anatomy 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- 210000002418 meninge Anatomy 0.000 claims description 2
- 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 claims description 2
- 208000036707 mucopolysaccharidosis type 3C Diseases 0.000 claims description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims description 2
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 claims description 2
- 208000012224 mucopolysaccharidosis type IIIC Diseases 0.000 claims description 2
- 210000003446 pia mater Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 208000011985 sialidosis Diseases 0.000 claims description 2
- 108060007951 sulfatase Proteins 0.000 claims description 2
- 210000001103 thalamus Anatomy 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 102000035160 transmembrane proteins Human genes 0.000 claims description 2
- 108091005703 transmembrane proteins Proteins 0.000 claims description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 9
- 108020004459 Small interfering RNA Proteins 0.000 claims 7
- 102000026659 IL10 Human genes 0.000 claims 6
- 101100403745 Mus musculus Myot gene Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000000405 Clarin Human genes 0.000 claims 5
- 108050008883 Clarin Proteins 0.000 claims 5
- 241001630723 Lepophidium brevibarbe Species 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 108010044965 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase Proteins 0.000 claims 1
- 230000001976 improved effect Effects 0.000 abstract description 20
- 239000013646 rAAV2 vector Substances 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 description 119
- 101710197658 Capsid protein VP1 Proteins 0.000 description 119
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 119
- 101710108545 Viral protein 1 Proteins 0.000 description 119
- 229940024606 amino acid Drugs 0.000 description 32
- 235000009697 arginine Nutrition 0.000 description 32
- 230000000875 corresponding effect Effects 0.000 description 31
- 210000001508 eye Anatomy 0.000 description 16
- 238000011282 treatment Methods 0.000 description 8
- 102000024452 GDNF Human genes 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 239000013607 AAV vector Substances 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 208000037644 RPE65-related recessive retinopathy Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988131P | 2014-05-02 | 2014-05-02 | |
| US61/988,131 | 2014-05-02 | ||
| US201562114575P | 2015-02-10 | 2015-02-10 | |
| US62/114,575 | 2015-02-10 | ||
| PCT/US2015/028966 WO2015168666A2 (en) | 2014-05-02 | 2015-05-02 | Aav vectors for retinal and cns gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2946593A1 true CA2946593A1 (en) | 2015-11-05 |
Family
ID=53189202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2946593A Pending CA2946593A1 (en) | 2014-05-02 | 2015-05-02 | Aav vectors for retinal and cns gene therapy |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10982228B2 (OSRAM) |
| EP (3) | EP3913061A1 (OSRAM) |
| JP (4) | JP6741591B2 (OSRAM) |
| KR (3) | KR20160147974A (OSRAM) |
| CN (2) | CN106661591B (OSRAM) |
| AU (3) | AU2015252797C1 (OSRAM) |
| CA (1) | CA2946593A1 (OSRAM) |
| CL (2) | CL2016002713A1 (OSRAM) |
| CR (1) | CR20160555A (OSRAM) |
| DK (1) | DK3137497T4 (OSRAM) |
| DO (1) | DOP2016000280A (OSRAM) |
| EA (1) | EA034355B1 (OSRAM) |
| ES (1) | ES2879636T5 (OSRAM) |
| FI (1) | FI3137497T4 (OSRAM) |
| GT (1) | GT201600227A (OSRAM) |
| HR (1) | HRP20211024T4 (OSRAM) |
| HU (1) | HUE054768T2 (OSRAM) |
| IL (2) | IL292951B2 (OSRAM) |
| LT (1) | LT3137497T (OSRAM) |
| MX (2) | MX2016014220A (OSRAM) |
| MY (1) | MY188987A (OSRAM) |
| PE (1) | PE20170260A1 (OSRAM) |
| PH (1) | PH12016502046A1 (OSRAM) |
| PL (1) | PL3137497T5 (OSRAM) |
| PT (1) | PT3137497T (OSRAM) |
| RS (1) | RS62078B2 (OSRAM) |
| SG (3) | SG10201912977RA (OSRAM) |
| SI (1) | SI3137497T2 (OSRAM) |
| TW (1) | TWI686476B (OSRAM) |
| UY (1) | UY36106A (OSRAM) |
| WO (1) | WO2015168666A2 (OSRAM) |
| ZA (1) | ZA201606763B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12201658B2 (en) | 2015-04-08 | 2025-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral gene therapy as treatment for cholesterol storage disease or disorder |
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| DK3421603T3 (da) | 2009-05-02 | 2022-01-10 | Genzyme Corp | Genterapi for neurodegenerative forstyrrelser |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US9102949B2 (en) | 2010-04-23 | 2015-08-11 | University Of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| EP2561075B1 (en) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| WO2011133874A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Multicistronic expression constructs |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP3318634A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations |
| DK2699270T3 (en) | 2011-04-22 | 2017-10-02 | Univ California | ADENO-ASSOCIATED VIRUS VIRUSES WITH VARIANT CAPSID AND METHODS FOR USING IT |
| HK1222093A1 (zh) * | 2013-05-15 | 2017-06-23 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| ES2897508T3 (es) | 2013-05-31 | 2022-03-01 | Univ California | Variantes de virus adenoasociados y métodos de uso de las mismas |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| WO2015127128A2 (en) | 2014-02-19 | 2015-08-27 | University Of Massachusetts | Recombinant aavs having useful transcytosis properties |
| JP6689249B2 (ja) | 2014-03-17 | 2020-05-20 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 錐体細胞における増強された遺伝子発現のための組成物および方法 |
| AU2015231294B2 (en) | 2014-03-18 | 2020-10-29 | University Of Massachusetts | rAAV-based compositions and methods for treating amyotrophic lateral sclerosis |
| US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
| PE20170260A1 (es) | 2014-05-02 | 2017-04-12 | Genzyme Corp | Vectores de aav para la terapia genica de la retina y el snc |
| ES2823948T3 (es) * | 2014-05-14 | 2021-05-10 | Esteve Pharmaceuticals Sa | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico |
| US10689653B2 (en) | 2014-06-03 | 2020-06-23 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| WO2016054557A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Novel high efficiency library-identified aav vectors |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| CA2964272A1 (en) | 2014-10-21 | 2016-04-28 | Guangping Gao | Recombinant aav variants and uses thereof |
| CA2976082A1 (en) * | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
| JP2018506304A (ja) | 2015-02-10 | 2018-03-08 | ジェンザイム・コーポレーション | バリアントＲＮＡｉ |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| AU2016226289B2 (en) | 2015-03-02 | 2021-04-29 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| CA2979229A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
| US10883117B2 (en) | 2015-03-24 | 2021-01-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| MX387517B (es) | 2015-04-06 | 2025-03-18 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| CN108137655B (zh) | 2015-09-28 | 2022-04-22 | 北卡罗来纳-查佩尔山大学 | 逃避抗体的病毒载体的方法和组合物 |
| CA3002980A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| DK3364997T5 (da) | 2015-10-22 | 2024-09-30 | Univ Massachusetts | Aspartoacylase genterapi til behandling af canavans sygdom |
| EP3368054A4 (en) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
| DK3387137T3 (da) * | 2015-12-11 | 2021-05-03 | California Inst Of Techn | Målretningspeptider til styring af adeno-associerede virusser (aav`er) |
| SG10201912935WA (en) * | 2015-12-15 | 2020-02-27 | Genzyme Corp | Adeno-associated viral vectors for treating mucolipidosis type ii |
| CA3011939A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| US20190071681A1 (en) * | 2016-02-26 | 2019-03-07 | University Of Florida Research Foundation, Incorporated | Aav heparin mutants that display significantly improved eye and brain transduction |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| CN107287238B (zh) * | 2016-04-11 | 2020-10-16 | 厦门继景生物技术有限责任公司 | 一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物 |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| GB201608046D0 (en) | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| IL264070B2 (en) * | 2016-07-08 | 2023-03-01 | Univ Pennsylvania | Methods and preparations for the treatment of disorders and diseases involving rdh12 |
| US11458211B2 (en) | 2016-07-12 | 2022-10-04 | The University Of Manchester | Gene therapy |
| KR20230039779A (ko) | 2016-07-29 | 2023-03-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법 |
| WO2018035213A1 (en) * | 2016-08-16 | 2018-02-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| JP2019524162A (ja) * | 2016-08-18 | 2019-09-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | モジュラーＡＡＶ送達システムによるＣＲＩＳＰＲ−Ｃａｓゲノム編集 |
| US20210283222A1 (en) * | 2016-08-19 | 2021-09-16 | Calimmune, Inc. | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus |
| JP7165410B2 (ja) | 2016-08-19 | 2022-11-04 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| JP7035033B2 (ja) | 2016-09-28 | 2022-03-14 | コーバー、インコーポレイテッド | 治療用ＭＯＴＳ－ｃ関連ペプチド |
| EP3518985A4 (en) * | 2016-09-29 | 2020-08-05 | University of Florida Research Foundation, Incorporated | AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES |
| WO2018071831A1 (en) | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| KR20190088561A (ko) | 2016-12-07 | 2019-07-26 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
| WO2018145009A1 (en) * | 2017-02-06 | 2018-08-09 | University Of Tennessee Research Foundation | Dna-zyme based methods & compositions for treating huntington's disease |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| MX2019012113A (es) | 2017-04-14 | 2020-09-10 | Univ Nat Taiwan | Terapia génica para la deficiencia de la aadc. |
| WO2018200419A1 (en) * | 2017-04-23 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Viral vectors comprising engineered aav capsids and compositions containing the same |
| JP2020518259A (ja) * | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| CA3059213A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
| WO2018209154A1 (en) * | 2017-05-10 | 2018-11-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses |
| WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| WO2019006182A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF |
| KR102850887B1 (ko) | 2017-08-03 | 2025-08-28 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
| CA3059995A1 (en) | 2017-08-28 | 2019-03-07 | The Regents Of The University Of California | Adeno-associated virus capsid variants and methods of use thereof |
| WO2019060686A1 (en) | 2017-09-22 | 2019-03-28 | University Of Massachusetts | NEW DUAL EXPRESSION VECTORS OF SOD1 AND USES THEREOF |
| WO2019060649A1 (en) * | 2017-09-22 | 2019-03-28 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
| EP3684932A1 (en) | 2017-09-22 | 2020-07-29 | Genzyme Corporation | Variant rnai |
| EP3697896A1 (en) * | 2017-10-16 | 2020-08-26 | Vigeneron GmbH | Aav vectors |
| US11723988B2 (en) | 2017-10-20 | 2023-08-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector |
| CA3082410A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| WO2019099696A1 (en) * | 2017-11-15 | 2019-05-23 | The Regents Of The University Of Michigan | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
| AU2018369975B2 (en) * | 2017-11-15 | 2022-05-19 | Friedrich Miescher Institute For Biomedical Research | Primate retinal pigment epithelium cell-specific promoter |
| EP3714055A1 (en) | 2017-11-21 | 2020-09-30 | CRISPR Therapeutics AG | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| CN108085316B (zh) * | 2017-12-25 | 2021-02-09 | 中国人民解放军第四军医大学 | 一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法 |
| EP3768327A4 (en) * | 2018-03-23 | 2022-04-13 | The Trustees of Columbia University in the City of New York | GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| SG11202009451VA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| AU2019261646A1 (en) | 2018-04-27 | 2020-11-12 | Spacecraft Seven, Llc | Gene therapy for CNS degeneration |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| BR112020023082A2 (pt) | 2018-05-15 | 2021-02-09 | Voyager Therapeutics, Inc. | composições e métodos para o tratamento de doença de parkinson |
| US12338267B2 (en) | 2018-05-15 | 2025-06-24 | President And Fellows Of Harvard College | Viral vectors exhibiting improved gene delivery properties |
| US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
| EP3802836A4 (en) * | 2018-06-01 | 2022-10-19 | University of Florida Research Foundation, Incorporated | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA |
| US12163129B2 (en) | 2018-06-08 | 2024-12-10 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| WO2020028816A1 (en) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variant rnai against alpha-synuclein |
| CN109022487A (zh) * | 2018-08-15 | 2018-12-18 | 上海市第人民医院 | 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物 |
| CN113966399A (zh) | 2018-09-26 | 2022-01-21 | 加州理工学院 | 用于靶向基因疗法的腺相关病毒组合物 |
| CA3114621A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| AU2019357602A1 (en) * | 2018-10-10 | 2021-05-13 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20210348135A1 (en) * | 2018-10-12 | 2021-11-11 | Genzyme Corporation | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| US20230061069A1 (en) * | 2018-11-13 | 2023-03-02 | Jayandharan Giridhara Rao | A process for producing a plurality of sumoylation target-site modified aav vector and product thereof |
| CN113227126A (zh) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | 成纤维细胞生长因子21(fgf21)基因治疗 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| WO2020140007A1 (en) * | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| TWI848038B (zh) * | 2019-01-04 | 2024-07-11 | 美商奧崔基尼克斯製藥公司 | 用於治療威爾森氏症之基因療法構築體 |
| AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
| CA3125294A1 (en) * | 2019-01-23 | 2020-07-30 | University Of Florida Research Foundation, Incorporated | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
| AU2020216135A1 (en) | 2019-01-28 | 2021-08-05 | Cohbar, Inc. | Therapeutic peptides |
| DK3850089T5 (da) | 2019-02-04 | 2024-08-19 | Freeline Therapeutics Ltd | Polynukleotider |
| EP3934698A1 (en) * | 2019-03-04 | 2022-01-12 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| CA3132369A1 (en) | 2019-03-04 | 2020-09-10 | Duke University | Compositions and methods for the diagnosis and treatment of retinopathies |
| WO2020182722A1 (en) * | 2019-03-08 | 2020-09-17 | Universite Paris-Saclay | Improved therapeutic method for rare ocular diseases by gene replacement |
| CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
| CN114026115A (zh) * | 2019-04-10 | 2022-02-08 | 普利维尔治疗公司 | 用于溶酶体病症的基因疗法 |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2020232005A1 (en) * | 2019-05-13 | 2020-11-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polymer-based implant for retinal therapy and methods of making and using the same |
| CA3141020A1 (en) * | 2019-05-17 | 2020-11-26 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy targeting retinal cells |
| WO2020251954A1 (en) * | 2019-06-10 | 2020-12-17 | Homology Medicines, Inc. | Adeno-associated virus compositions for arsa gene transfer and methods of use thereof |
| JP2022539156A (ja) | 2019-06-27 | 2022-09-07 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ヒアルロン酸を用いた眼組織へのａａｖ媒介形質導入の増強 |
| US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
| RS66255B1 (sr) * | 2019-07-15 | 2024-12-31 | Meiragtx Uk Ii Ltd | Modifikovani proteini aav kapsida za lečenje artritične bolesti |
| CN110295151A (zh) * | 2019-07-17 | 2019-10-01 | 博鑫仪器(天津)有限公司 | 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法 |
| US20220281930A1 (en) * | 2019-08-23 | 2022-09-08 | Duke University | Compositions and methods for the treatment of pathological pain and itch |
| EP4025258A4 (en) * | 2019-09-03 | 2023-09-06 | University of Cincinnati | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| IL291944A (en) * | 2019-10-10 | 2022-06-01 | Solid Biosciences Inc | Modified aav capsids and uses thereof |
| TW202128736A (zh) * | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| JP7697943B2 (ja) * | 2019-10-23 | 2025-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 導入遺伝子発現のｄｒｇ特異的低減のための組成物 |
| EP4055030A4 (en) * | 2019-11-08 | 2024-05-22 | President And Fellows Of Harvard College | VIRAL CAPSID POLYPEPTIDES |
| CN113025618B (zh) * | 2019-12-24 | 2024-02-06 | 朗信启昇(苏州)生物制药有限公司 | 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用 |
| US20210261625A1 (en) * | 2020-01-29 | 2021-08-26 | Genzyme Corporation | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
| CN115485024A (zh) * | 2020-02-07 | 2022-12-16 | 纽约市哥伦比亚大学理事会 | 重编程代谢组以延迟发病或治疗神经变性 |
| WO2021167919A1 (en) * | 2020-02-18 | 2021-08-26 | The University Of North Carolina At Chapel Hill | Aav capsid-promoter interactions and cell selective gene expression |
| WO2021173984A2 (en) * | 2020-02-28 | 2021-09-02 | University Of Massachusetts | Oligonucleotides for prnp modulation |
| US12257320B2 (en) | 2020-03-11 | 2025-03-25 | Massachusetts Eye And Ear Infirmary | Gene therapy for NMNAT1-associated retinal degeneration |
| EP4126911A1 (en) * | 2020-03-31 | 2023-02-08 | University of Massachusetts | Aav capsids variants and uses thereof |
| JP2023523573A (ja) * | 2020-04-14 | 2023-06-06 | ジェネトン | 酸性セラミダーゼ欠乏症を処置するためのベクター |
| IL297200A (en) | 2020-04-15 | 2022-12-01 | Voyager Therapeutics Inc | tau binding compounds |
| CN116096734A (zh) | 2020-05-13 | 2023-05-09 | 沃雅戈治疗公司 | Aav衣壳的向性的重定向 |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| WO2021252989A2 (en) * | 2020-06-13 | 2021-12-16 | Oculogenex Inc. | Aav-mediated gene transfer for retinopathy |
| CN113952472A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| WO2022026409A1 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| IL300187A (en) | 2020-08-05 | 2023-03-01 | Spacecraft Seven Llc | Gene therapy CSRP3 (protein 3 rich in cysteine and glycine) |
| AU2021320902A1 (en) | 2020-08-07 | 2023-04-06 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
| CN116745409A (zh) | 2020-08-19 | 2023-09-12 | 萨雷普塔治疗公司 | 用于治疗雷特综合征的腺相关病毒载体 |
| CN116249541A (zh) * | 2020-09-04 | 2023-06-09 | 俄亥俄州创新基金会 | 具有增强的转导效率并在脑中广泛分布的重组腺相关病毒载体的新型工程化衣壳血清型 |
| US20230392166A1 (en) * | 2020-10-21 | 2023-12-07 | Wisconsin Alumni Research Foundation | Anti-apoptotic vector and method of using the same |
| US20220160825A1 (en) * | 2020-11-25 | 2022-05-26 | The Penn State Research Foundation | Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion |
| AU2022224667A1 (en) * | 2021-02-22 | 2023-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Viral vector-based gene therapy for ocular conditions |
| CN115044614B (zh) * | 2021-03-09 | 2023-10-20 | 上海目镜生物医药科技有限公司 | 一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用 |
| JP2024517737A (ja) * | 2021-04-26 | 2024-04-23 | グレース サイエンス， エルエルシー | Ｎｇｙｌ１欠損症を治療する組成物及び方法 |
| EP4399314A4 (en) * | 2021-09-06 | 2025-09-10 | Huidagene Therapeutics Singapore Pte Ltd | TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65 |
| WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| US20250051750A1 (en) | 2021-11-29 | 2025-02-13 | Shanghai Regenelead Therapies Co., Ltd. | Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| EP4499154A1 (en) * | 2022-03-25 | 2025-02-05 | REGENXBIO Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| CN119487188A (zh) * | 2022-04-19 | 2025-02-18 | 上海天泽云泰生物医药有限公司 | 用于治疗神经退行性障碍的重组aav载体 |
| EP4514402A2 (en) * | 2022-04-25 | 2025-03-05 | Myrtelle Inc. | Treatments of disorders of myelin |
| JP2025514145A (ja) | 2022-04-25 | 2025-05-02 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 視力喪失を処置するための方法及び組成物 |
| JP2025517628A (ja) | 2022-05-06 | 2025-06-10 | ノバルティス アーゲー | 新規の組換えａａｖ ｖｐ２融合ポリペプチド |
| WO2023240220A1 (en) * | 2022-06-09 | 2023-12-14 | The University Of North Carolina At Chapel Hill | Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| CA3261363A1 (en) | 2022-07-08 | 2024-01-11 | Ospedale San Raffaele S.R.L. | TRANSGENIC CASSETTES |
| EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
| EP4555097A2 (en) * | 2022-07-12 | 2025-05-21 | The Research Institute at Nationwide Children's Hospital | Adeno-associated virus gene therapy products and methods |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024218311A1 (fr) | 2023-04-21 | 2024-10-24 | Pulsesight Therapeutics | Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine |
| GB202306952D0 (en) * | 2023-05-11 | 2023-06-28 | Neurochase Innovations Ltd | Method |
| US20250197862A1 (en) | 2023-12-15 | 2025-06-19 | Genzyme Corporation | ARTIFICIAL microRNAs TARGETING TAU |
| WO2025160452A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Methods for fus-based delivery of viral particles to the brain |
| WO2025160434A1 (en) | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting huntington's disease |
| WO2025160429A1 (en) | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting snca |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US5735815A (en) | 1993-07-26 | 1998-04-07 | Sentinel Medical, Inc. | Method of using fluid jet surgical cutting tool |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| NZ500427A (en) | 1997-04-21 | 2002-12-20 | Univ Florida | The use of ribozyme treatment for retinal diseases |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| JP2002516295A (ja) | 1998-05-27 | 2002-06-04 | アビジェン， インコーポレイテッド | Ａａｖベクターの対流増加送達 |
| ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
| AU6972301A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Duplexed parvovirus vectors |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
| US8802080B2 (en) * | 2002-05-01 | 2014-08-12 | University Of Florida Research Foundation, Inc. | Raav expression systems for genetic modification of specific capsid proteins |
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| EP1618201A1 (en) * | 2003-05-01 | 2006-01-25 | University of Florida Research Foundation, Inc. | Vp2 - modified raav vectors and uses thereof |
| DK2277996T3 (da) | 2003-05-21 | 2014-10-20 | Genzyme Corp | Fremgangsmåder til fremstilling af præparationer af rekombinante aav-virioner, der i hovedsagen er fri for tomme capsider |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| PT2657248T (pt) * | 2003-06-19 | 2017-06-26 | Genzyme Corp | Viriões aav com imunorreatividade diminuída e seus usos |
| PL1807009T3 (pl) | 2004-10-05 | 2015-06-30 | Genzyme Corp | Stopniowana kaniula |
| EP2359865B1 (en) * | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| CA2619882C (en) | 2005-08-23 | 2015-05-26 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
| WO2007089632A2 (en) * | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| PT2019683T (pt) | 2006-04-25 | 2017-03-17 | Univ California | Administração de fatores de crescimento para o tratamento de distúrbios do snc |
| EP2023949A4 (en) | 2006-04-26 | 2009-08-26 | Univ California | COMPOSITIONS AND METHODS FOR CONVECTION-REINFORCED RELEASE OF NEUROTHERAPEUTICS WITH HIGH MOLECULAR WEIGHT |
| CN101495624A (zh) * | 2006-04-28 | 2009-07-29 | 宾夕法尼亚州立大学托管会 | 衣壳免疫原性降低的经修饰aav载体及其用途 |
| BRPI0811648A2 (pt) | 2007-05-17 | 2014-11-11 | Medgenesis Therapeutix Inc | Cateter para administrar um agente a partir de um suprimento para tecido visado de um organismo de mamífero, e, métodos para administrar um agente para tecido visado disposto além de tecido intermediário de um organismo de mamífero, e para administrar um agente a partir de um suprimento para tecido visado disposto além de tecido intermediário de um organismo de mamífero |
| WO2009105690A2 (en) | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| CA2751266A1 (en) | 2009-01-29 | 2010-08-05 | Krystof Bankiewicz | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
| EP2396343B1 (en) * | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| JP5956331B2 (ja) | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えａａｖベクターの改良された精製方法 |
| US9102949B2 (en) | 2010-04-23 | 2015-08-11 | University Of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| DK2699270T3 (en) | 2011-04-22 | 2017-10-02 | Univ California | ADENO-ASSOCIATED VIRUS VIRUSES WITH VARIANT CAPSID AND METHODS FOR USING IT |
| TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| WO2015012501A1 (ko) | 2013-07-25 | 2015-01-29 | 주식회사 스마트캐스터 | 비공기압 바퀴 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| PE20170260A1 (es) | 2014-05-02 | 2017-04-12 | Genzyme Corp | Vectores de aav para la terapia genica de la retina y el snc |
-
2015
- 2015-05-02 PE PE2016002164A patent/PE20170260A1/es unknown
- 2015-05-02 IL IL292951A patent/IL292951B2/en unknown
- 2015-05-02 CR CR20160555A patent/CR20160555A/es unknown
- 2015-05-02 CN CN201580035996.2A patent/CN106661591B/zh active Active
- 2015-05-02 PL PL15723386.7T patent/PL3137497T5/pl unknown
- 2015-05-02 AU AU2015252797A patent/AU2015252797C1/en active Active
- 2015-05-02 EP EP21159585.5A patent/EP3913061A1/en active Pending
- 2015-05-02 EP EP15723386.7A patent/EP3137497B2/en active Active
- 2015-05-02 SI SI201531642T patent/SI3137497T2/sl unknown
- 2015-05-02 PT PT157233867T patent/PT3137497T/pt unknown
- 2015-05-02 CN CN202111211678.0A patent/CN114231563B/zh active Active
- 2015-05-02 EP EP25153064.8A patent/EP4600255A3/en active Pending
- 2015-05-02 HR HRP20211024TT patent/HRP20211024T4/hr unknown
- 2015-05-02 SG SG10201912977RA patent/SG10201912977RA/en unknown
- 2015-05-02 ES ES15723386T patent/ES2879636T5/es active Active
- 2015-05-02 EA EA201692206A patent/EA034355B1/ru not_active IP Right Cessation
- 2015-05-02 JP JP2016564301A patent/JP6741591B2/ja active Active
- 2015-05-02 LT LTEP15723386.7T patent/LT3137497T/lt unknown
- 2015-05-02 US US15/308,335 patent/US10982228B2/en active Active
- 2015-05-02 WO PCT/US2015/028966 patent/WO2015168666A2/en not_active Ceased
- 2015-05-02 RS RS20210849A patent/RS62078B2/sr unknown
- 2015-05-02 HU HUE15723386A patent/HUE054768T2/hu unknown
- 2015-05-02 CA CA2946593A patent/CA2946593A1/en active Pending
- 2015-05-02 KR KR1020167033392A patent/KR20160147974A/ko not_active Ceased
- 2015-05-02 KR KR1020257031397A patent/KR20250141850A/ko active Pending
- 2015-05-02 FI FIEP15723386.7T patent/FI3137497T4/fi active
- 2015-05-02 SG SG11201607991WA patent/SG11201607991WA/en unknown
- 2015-05-02 SG SG10201809739QA patent/SG10201809739QA/en unknown
- 2015-05-02 MY MYPI2016703542A patent/MY188987A/en unknown
- 2015-05-02 DK DK15723386.7T patent/DK3137497T4/da active
- 2015-05-02 IL IL248102A patent/IL248102B/en unknown
- 2015-05-02 MX MX2016014220A patent/MX2016014220A/es unknown
- 2015-05-02 KR KR1020247006248A patent/KR102863726B1/ko active Active
- 2015-05-04 UY UY0001036106A patent/UY36106A/es not_active Application Discontinuation
- 2015-05-04 TW TW104114126A patent/TWI686476B/zh active
-
2016
- 2016-09-30 ZA ZA2016/06763A patent/ZA201606763B/en unknown
- 2016-10-13 PH PH12016502046A patent/PH12016502046A1/en unknown
- 2016-10-19 DO DO2016000280A patent/DOP2016000280A/es unknown
- 2016-10-24 GT GT201600227A patent/GT201600227A/es unknown
- 2016-10-25 CL CL2016002713A patent/CL2016002713A1/es unknown
- 2016-10-28 MX MX2022012490A patent/MX2022012490A/es unknown
-
2018
- 2018-01-19 CL CL2018000170A patent/CL2018000170A1/es unknown
-
2020
- 2020-06-24 JP JP2020108310A patent/JP7174011B2/ja active Active
-
2021
- 2021-01-15 AU AU2021200242A patent/AU2021200242B9/en active Active
- 2021-03-05 US US17/194,009 patent/US12241078B2/en active Active
-
2022
- 2022-11-02 JP JP2022175918A patent/JP7682142B2/ja active Active
-
2023
- 2023-12-20 AU AU2023285817A patent/AU2023285817A1/en active Pending
-
2024
- 2024-12-27 JP JP2024231483A patent/JP2025065116A/ja active Pending
-
2025
- 2025-01-30 US US19/041,853 patent/US20250320522A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12201658B2 (en) | 2015-04-08 | 2025-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral gene therapy as treatment for cholesterol storage disease or disorder |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12241078B2 (en) | AAV vectors for retinal and CNS gene therapy | |
| HK40064049A (en) | Aav vectors for retinal and cns gene therapy | |
| HK40071052A (en) | Aav vectors for retinal and cns gene therapy | |
| HK40071052B (zh) | 用於视网膜及cns基因疗法的aav载体 | |
| HK1234076B (en) | Aav vectors for retinal and cns gene therapy | |
| BR122020026753B1 (pt) | Uso de uma partícula de vírus adenoassociado recombinante (raav) na fabricação de um medicamento para distribuir um ácido nucleico heterólogo ao olho de um indivíduo | |
| BR112016025263B1 (pt) | Usos: de uma partícula de vírus adenoassociado recombinante (raav), de um kit, e de uma composição compreendendo uma partícula de vírus adenoassociado recombinante (raav) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |
|
| EEER | Examination request |
Effective date: 20200427 |